Rik Bryan qualified in Medicine at the University of Birmingham and subsequently entered surgical training. After completing a PhD in bladder cancer cadherin biology he became a Specialist Registrar in Urology. After 4-years as a Specialist Registrar, Rik left clinical urology to assist with the set-up of the Bladder Cancer Prognosis Programme (BCPP) at the University of Birmingham, and was subsequently appointed as a Senior Research Fellow in the Institute of Cancer & Genomic Sciences. Rik is now the Chief Investigator of BCPP which incorporates the SELENIB clinical trial, and is also a member of the Trial Management Group for the POUT trial with responsibility for biospecimen collection and translational research. Rik sits on the Council of The Royal Society of Medicine Section of Urology, and is the elected Honorary Secretary for the 2015-16 session.
Rik has an interest in all aspects of bladder cancer, from optical technologies and endoscopic surgical techniques to biomarker discovery and molecular pathways. His particular interests are narrow band imaging cystoscopy, urinary biomarkers, and genomics, and he has a track record of publication in these specific areas.